Tempus AI slides after missing Q4 EBITDA target
Cancer diagnostics company and sometimes retail shareholder favorite Tempus AI reported soft Q4 adjusted EBITDA numbers late Tuesday, sending shares lower in the after-hours session.
It reported:
Q4 revenue of $367.2 million vs. FactSet’s expectation of $362.8 million.
An adjusted loss per share of $0.04 vs. the $0.04 loss estimated.
Adjusted EBITDA of $12.9 million vs. expectations for $22 million, per FactSet.
Since going public in June 2024, Tempus has been a volatile stock that has both doubled — and cratered — on multiple occasions. That spectacle has at times captured the attention of retail traders who’ve tried to ride the waves.
Of late, the wave has been breaking bad, with shares down more than 30% since the stock hit a record high on October 8, 2025
Still, the company is now adjusted EBITDA positive. That, CEO Eric Lefkofsky told us last year, is the first milestone on Tempus’ journey to profitability, a mark that analysts think will take until at least next year for the company to hit.